|
26.04.24 |
GNW-Adhoc: JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension |
|
23.04.24 |
GNW-Adhoc: Idorsia publishes an invitation to a bondholder meeting |
|
17.04.24 |
GNW-Adhoc: Idorsia publishes a Financial Status required for an upcoming bondholder meeting |
|
11.04.24 |
GNW-Adhoc: Idorsia takes steps to address short-term liquidity needs |
|
22.03.24 |
GNW-Adhoc: Idorsia thanks Guy Braunstein for his years of service as he retires |
|
20.03.24 |
ROUNDUP/Aktien Europa Schluss: Moderate Verluste vor US-Zinsentscheid |
|
20.03.24 |
Aktien Europa: Verluste vor US-Zinsentscheid - Kering belastet Luxusgüterbranche |
|
20.03.24 |
GNW-Adhoc: US FDA approves Idorsia's once-daily TRYVIO (aprocitentan) - the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with other antihypertensives |
|
18.03.24 |
GNW-Adhoc: Idorsia and Viatris successfully close the transaction for the global research and development collaboration |
|
28.02.24 |
GNW-Adhoc: Idorsia and Viatris enter into a significant global research and development collaboration |
|
28.02.24 |
Idorsia and Viatris enter into a significant global research and development collaboration |
|
10.01.24 |
GNW-Adhoc: Idorsia presents at the J.P. Morgan Healthcare Conference - Adapting Idorsia for sustainable value creation |
|
03.11.23 |
New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the American Society of Nephrology Kidney Week 2023 |
|
23.05.22 |
Aktien, Märkte, Branchen in Zahlen - Europas Top Biotech-Aktien |
|
23.05.22 |
News aus dem Börse Express PDF vom 23.05.2022 (Spiel, Satz, Fragezeichen - Zahlen von betathome.com, Marinomed - ams Osram, Erste Group, OMV, SBO, vienna Insurance Group, Wienerberger - Europäische Biotechbranche - Die Einbahnstraße Aktienmarkt ...) |